Under non-tumor purity conditions, the downregulation of KLRB1 expression was significantly associated with changes in the expression levels of immune cell markers such as CD8A, CD8B, CD3D, CD3E, CD2, CD19, CD79A, CD86, PDCD1, CTLA4, LAG3, HAVCR2, GZMB, CSF1R, CCL2, CD68, IL10, NOS2, IRF5, PTGS2, CD163, VSIG4, MS4A4A, CEACAM8, ITGAM, CCR7, KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS4, HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DPA1, CD1C, ITGAX, TBX21, STAT4, STAT1, IFNG, TNF, GATA3, STAT6, STAT5A, IL13, IL21, IL17A, FOXP3, CCR8, STAT5B, and TGFB1 (Table 3 and Fig. 13). The gene discussed is GATA3; the disease is neoplasm.